Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality in motion Quality Strong, Valuation Fairly Valued, Momentum Bullish
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Alembic Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Vadodara, Gujarat. The company manufactures and markets pharmaceutical products, including active pharmaceutical ingredients (APIs) and formulations, and has a presence in the macrolide anti-infective drug segment.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #36 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 1 Oct 2025 | Nirayu Private Limited | Promoter group | Buy | 0 | ₹0 |
| 29 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 29 Sep 2025 | Nirayu Private Limited | Promoter group | Buy | 0 | ₹0 |
| 17 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 11 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 9 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 5 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 3 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 3 Sep 2025 | Chirayu Ramanbhai Amin HUF | Promoter group | Buy | 0 | ₹0 |
| 28 Mar 2025 | NIRAYU LIMITED | Promoter group | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 11 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 25,903 | 611.2500 | BSE |
| 11 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 25,903 | 611.2500 | BSE |
| 11 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 184,251 | 611.2500 | BSE |
| 11 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 184,251 | 611.2500 | BSE |
| 3 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 25,151 | 604.6500 | NSE |
| 3 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 25,151 | 604.6500 | NSE |
| 3 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 178,908 | 604.6500 | NSE |
| 3 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 178,908 | 604.6500 | NSE |
| 19 Sep 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 27,364 | 609.9000 | BSE |
| 19 Sep 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 27,364 | 609.9000 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 29 Jul 2026 | Dividend - Rs 12 Per Share | 12.0000 | 29 Jul 2026 |
| 29 Jul 2025 | Dividend - Rs 11 Per Share | 11.0000 | 29 Jul 2025 |
| 15 Jul 2024 | Dividend - Rs 11 Per Share | 11.0000 | 15 Jul 2024 |
| 28 Jul 2023 | Dividend - Rs 8 Per Share | 8.0000 | 28 Jul 2023 |
| 17 Aug 2022 | Interim Dividend - Rs 10 Per Share | 10.0000 | 18 Aug 2022 |
| 19 Jul 2021 | Annual General Meeting/Dividend - Rs 14 Per Share | 14.0000 | — |
| 16 Mar 2020 | Interim Dividend - Rs 7 Per Share Special Dividend - Rs 3 Per Share | 7.0000 | 17 Mar 2020 |
| 18 Jul 2019 | Annual General Meeting/Dividend Rs 5.50/- | 5.5000 | — |
| 18 Jul 2018 | Annual General Meeting/Dividend- Rs 4 Per Share (Purpose Revised) | 4.0000 | — |
| 11 Jul 2017 | Annual General Meeting/Dividend -Rs 4/- Per Share | 4.0000 | — |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 4 Aug 2026 | Financial Results/Other business matters | Yes |
| 15 May 2026 | Financial Results/Dividend | Yes |
| 5 Feb 2026 | Financial Results | Yes |
| 4 Nov 2025 | Financial Results/Other business matters | Yes |
| 5 Aug 2025 | Financial Results/Other business matters | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 29 Sep 2026 | Insider Trading / SAST | Alembic Pharmaceuticals Ltd - 533573 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 |
| 28 Sep 2026 | Insider Trading / SAST | Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window |
| 28 Sep 2026 | Trading Window | Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 18 Sep 2026 | Company Update | Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 18 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet |
| 16 Sep 2026 | Company Update | Alembic Pharmaceuticals Ltd - 533573 - Update On USFDA Inspection Conducted During 3Rd March, 2025 To 7Th March, 2025 At Bioequivalence Facility Located At Vadodara, Gujarat. |
| 16 Sep 2026 | Updates | Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat. |
| 11 Sep 2026 | Company Update | Alembic Pharmaceuticals Ltd - 533573 - Intimation Regarding Successful Completion Of Unannounced USFDA Onsite Bioequivalence Inspection. |
| 11 Sep 2026 | General Updates | Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited s Bioequivalence Facility in Vadodara, Gujarat |
| 7 Sep 2026 | General Updates | Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Wholly Owned Subsidiary Company |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
